

Michael Baumann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6865012/publications.pdf>

Version: 2024-02-01

342
papers

15,841
citations

15466

65
h-index

25716

108
g-index

371
all docs

371
docs citations

371
times ranked

16927
citing authors

#	ARTICLE	IF	CITATIONS
1	Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-â€˜staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. <i>European Urology Oncology</i> , 2022, 5, 44-51.	2.6	26
2	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2022, 167, 300-307.	0.3	5
3	Personalised radiation therapy taking both the tumour and patient into consideration. <i>Radiotherapy and Oncology</i> , 2022, 166, A1-A5.	0.3	7
4	Response to comment on â€œBiomarker signatures for primary radiochemotherapy of locally advanced HNSCCâ€•. <i>Radiotherapy and Oncology</i> , 2022, , .	0.3	0
5	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC â€˜ Hypothesis generation on a multicentre cohort of the DTKK-ROG. <i>Radiotherapy and Oncology</i> , 2022, 169, 8-14.	0.3	5
6	Subjective memory impairment in glioma patients with curative radiotherapy. <i>Radiotherapy and Oncology</i> , 2022, , .	0.3	0
7	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2022, 171, 91-100.	0.3	4
8	Importance of long-term follow up to address long-term effectiveness and toxicity of radiotherapy. <i>Radiotherapy and Oncology</i> , 2022, 170, 1-3.	0.3	1
9	Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P). <i>Cancers</i> , 2022, 14, 2073.	1.7	7
10	A Novel 2-Metogene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. <i>Cancers</i> , 2022, 14, 3031.	1.7	2
11	ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. <i>Pharmacogenomics Journal</i> , 2021, 21, 37-46.	0.9	6
12	Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase III clinical trial â€˜ PaCa-DD-041 (Eudra-CT) Tj ETQq0 0 0 10BT /Overlack 10 Tf		
13	Results of a randomized controlled phase III trial: efficacy of polyphenol-containing cystus tea mouthwash solution for the reduction of mucositis in head and neck cancer patients undergoing external beam radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 63-73.	1.0	10
14	Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial. <i>Radiotherapy and Oncology</i> , 2021, 155, 285-292.	0.3	12
15	Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 62-70.	0.9	8
16	MRI-guided Radiation Therapy: An Emerging Paradigm in Adaptive Radiation Oncology. <i>Radiology</i> , 2021, 298, 248-260.	3.6	83
17	Dual role of ER stress in response to metabolic co-targeting and radiosensitivity in head and neck cancer cells. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 3021-3044.	2.4	8
18	Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2021, 155, 204-211.	0.3	5

#	ARTICLE	IF	CITATIONS
19	GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. <i>Theranostics</i> , 2021, 11, 7844-7868.	4.6	70
20	Radiation oncology in the new virtual and digital era. <i>Radiotherapy and Oncology</i> , 2021, 154, A1-A4.	0.3	8
21	Solving problems is smart, preventing them is wise: Lessons learned from the 2nd International DKFZ Conference on Cancer Prevention. <i>International Journal of Cancer</i> , 2021, 148, 3086-3096.	2.3	1
22	Modelling of late side-effects following cranial proton beam therapy. <i>Radiotherapy and Oncology</i> , 2021, 157, 15-23.	0.3	6
23	Tyrosine Kinase c-MET as Therapeutic Target for Radiosensitization of Head and Neck Squamous Cell Carcinomas. <i>Cancers</i> , 2021, 13, 1865.	1.7	9
24	Sample-size calculation for preclinical dose-response experiments using heterogeneous tumour models. <i>Radiotherapy and Oncology</i> , 2021, 158, 262-267.	0.3	4
25	Value of functional in-vivo endpoints in preclinical radiation research. <i>Radiotherapy and Oncology</i> , 2021, 158, 155-161.	0.3	3
26	Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L. <i>Oncogene</i> , 2021, 40, 4214-4228.	2.6	27
27	Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiation Oncology</i> , 2021, 16, 141.	1.2	9
28	Identification of patient benefit from proton beam therapy in brain tumour patients based on dosimetric and NTCP analyses. <i>Radiotherapy and Oncology</i> , 2021, 160, 69-77.	0.3	8
29	Screening and Validation of Molecular Targeted Radiosensitizers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, e63-e74.	0.4	10
30	How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. <i>Pharmacoeconomics</i> , 2021, 39, 1243-1269.	1.7	94
31	In reply to the Letter to the Editor by Chen and Lui regarding "Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial" by A Dietrich et al.. <i>Radiotherapy and Oncology</i> , 2021, 161, 261-262.	0.3	0
32	The Porto European Cancer Research Summit 2021. <i>Molecular Oncology</i> , 2021, 15, 2507-2543.	2.1	7
33	Final Results of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1351-1360.	3.2	15
34	Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1131-1139.	0.4	5
35	Tumor DNA Methylome derived Epigenetic Fingerprint Identifies HPV negative Head and Neck Patients at Risk for Locoregional Recurrence after Postoperative Radiochemotherapy. <i>International Journal of Cancer</i> , 2021, 150, 603.	2.3	2
36	Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Cancers</i> , 2021, 13, 5595.	1.7	4

#	ARTICLE	IF	CITATIONS
37	The COVID-19 Pandemic and Cancer Patients in Germany: Impact on Treatment, Follow-Up Care and Psychological Burden. <i>Frontiers in Public Health</i> , 2021, 9, 788598.	1.3	14
38	Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo. <i>International Journal of Cancer</i> , 2020, 147, 472-477.	2.3	36
39	Dose-volume predictors of early esophageal toxicity in non-small cell lung cancer patients treated with accelerated-hyperfractionated radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 143, 44-50.	0.3	5
40	2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 15625.	1.6	34
41	Comparison of patient stratification by computed tomography radiomics and hypoxia positron emission tomography in head-and-neck cancer radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 15, 52-59.	1.2	2
42	Tribute to David Thwaites. <i>Radiotherapy and Oncology</i> , 2020, 153, 5-6.	0.3	0
43	Towards a cancer mission in Horizon Europe: recommendations. <i>Molecular Oncology</i> , 2020, 14, 1589-1615.	2.1	33
44	Dose dependent cerebellar atrophy in glioma patients after radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2020, 150, 262-267.	0.3	12
45	Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC. <i>Cancers</i> , 2020, 12, 3047.	1.7	19
46	Biomedical Research Goes Viral: Dangers and Opportunities. <i>Cell</i> , 2020, 181, 1189-1193.	13.5	6
47	Radiotherapy & Oncology during the COVID-19 pandemic. <i>Radiotherapy and Oncology</i> , 2020, 146, 221-222.	0.3	5
48	What will radiation oncology look like in 2050? A look at a changing professional landscape in Europe and beyond. <i>Molecular Oncology</i> , 2020, 14, 1577-1585.	2.1	22
49	Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy. <i>Radiotherapy and Oncology</i> , 2020, 149, 189-196.	0.3	41
50	Four decades with ESTRO. <i>Radiotherapy and Oncology</i> , 2020, 142, 1-5.	0.3	5
51	Radiation Oncology – Towards a mission-oriented approach to cancer. <i>Molecular Oncology</i> , 2020, 14, 1429-1430.	2.1	1
52	Neurocognitive function and quality of life after proton beam therapy for brain tumour patients. <i>Radiotherapy and Oncology</i> , 2020, 143, 108-116.	0.3	24
53	Radiotheranostics: a roadmap for future development. <i>Lancet Oncology</i> , The, 2020, 21, e146-e156.	5.1	151
54	Combined tumor plus nontumor interim FDG-PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer. <i>International Journal of Cancer</i> , 2020, 147, 1427-1436.	2.3	6

#	ARTICLE	IF	CITATIONS
55	Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 801-810.	1.2	10
56	Caring for patients with cancer in the COVID-19 era. <i>Nature Medicine</i> , 2020, 26, 665-671.	15.2	269
57	Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma. <i>Cancers</i> , 2020, 12, 871.	1.7	9
58	Preclinical In Vivo Evaluation of Novel Radiosensitizers by Local Tumor Control Experiments. <i>Cancer Drug Discovery and Development</i> , 2020, , 137-159.	0.2	1
59	Development and validation of NTCP models for acute side-effects resulting from proton beam therapy of brain tumours. <i>Radiotherapy and Oncology</i> , 2019, 130, 164-171.	0.3	27
60	CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2019, 130, 10-17.	0.3	44
61	Towards a Cancer Mission in Horizon Europe. <i>Molecular Oncology</i> , 2019, 13, 2301-2304.	2.1	5
62	FLASH radiotherapy International Workshop. <i>Radiotherapy and Oncology</i> , 2019, 139, 1-3.	0.3	34
63	Comparable radiation response of ex vivo and in vivo irradiated tumor samples determined by residual γ H2AX. <i>Radiotherapy and Oncology</i> , 2019, 139, 94-100.	0.3	11
64	Cancer Core Europe: A translational research infrastructure for a European mission on cancer. <i>Molecular Oncology</i> , 2019, 13, 521-527.	2.1	38
65	Continuously getting a bit more picky. <i>Radiotherapy and Oncology</i> , 2019, 130, 1.	0.3	3
66	Cancer Prevention Europe. <i>Molecular Oncology</i> , 2019, 13, 528-534.	2.1	70
67	The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. <i>Clinical Cancer Research</i> , 2019, 25, 3152-3163.	3.2	53
68	Residual γ H2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens. <i>Radiotherapy and Oncology</i> , 2019, 137, 24-31.	0.3	10
69	Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2019, 16, 40-47.	0.9	32
70	Cancer stem cells in radiation response: current views and future perspectives in radiation oncology. <i>International Journal of Radiation Biology</i> , 2019, 95, 900-911.	1.0	24
71	Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis. <i>Acta Oncologica</i> , 2019, 58, 916-925.	0.8	11
72	Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2019, 135, 43-50.	0.3	25

#	ARTICLE	IF	CITATIONS
73	Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 108-112.	0.9	9
74	Boosting the social impact of innovative cancer research – towards a mission-oriented approach to cancer. <i>Molecular Oncology</i> , 2019, 13, 497-501.	2.1	5
75	A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection. <i>Clinical Cancer Research</i> , 2019, 25, 1505-1516.	3.2	67
76	Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios. <i>British Journal of Radiology</i> , 2019, 92, 20180539.	1.0	12
77	Prognostic Value of Standardized Uptake Ratio in Patients with Trimodality Treatment of Locally Advanced Esophageal Carcinoma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 192-198.	2.8	23
78	Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?. <i>European Urology</i> , 2019, 75, 548-551.	0.9	36
79	German Cancer Consortium (DKTK) – A national consortium for translational cancer research. <i>Molecular Oncology</i> , 2019, 13, 535-542.	2.1	22
80	Expressing cytotoxic compounds in <i>Escherichia coli</i> Nissle 1917 for tumor-targeting therapy. <i>Research in Microbiology</i> , 2019, 170, 74-79.	1.0	48
81	FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients. <i>Radiotherapy and Oncology</i> , 2019, 130, 97-103.	0.3	14
82	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. <i>Lancet Oncology</i> , The, 2018, 19, e240-e251.	5.1	108
83	Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score – report of the Radiation Oncology Group (<sc>ROG</sc>) of the German Cancer Consortium (<sc>DKTK</sc>). <i>Cancer Medicine</i> , 2018, 7, 1742-1749.	1.3	34
84	Photon vs. proton radiochemotherapy: Effects on brain tissue volume and perfusion. <i>Radiotherapy and Oncology</i> , 2018, 128, 121-127.	0.3	48
85	The world needs new knowledge. <i>Radiotherapy and Oncology</i> , 2018, 126, 1-2.	0.3	5
86	Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis. <i>Radiotherapy and Oncology</i> , 2018, 127, 121-127.	0.3	37
87	Long-term quality of life in inoperable non-small cell lung cancer patients treated with conventionally fractionated compared to hyperfractionated accelerated radiotherapy – Results of the randomized CHARTWEL trial. <i>Radiotherapy and Oncology</i> , 2018, 126, 283-290.	0.3	7
88	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. <i>Radiotherapy and Oncology</i> , 2018, 127, 27-35.	0.3	17
89	Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. <i>Clinical Cancer Research</i> , 2018, 24, 1364-1374.	3.2	45
90	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 125-131.	0.3	24

#	ARTICLE	IF	CITATIONS
91	Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2018, 142, 1911-1925.	2.3	50
92	<i>Advances in Radiation Oncology</i> , , 2018, , .		0
93	Retrospective investigation of the prognostic value of the α 21 integrin expression in patients with head and neck squamous cell carcinoma receiving primary radio(chemo)therapy. <i>PLoS ONE</i> , 2018, 13, e0209479.	1.1	5
94	Heterogeneity of γ H2AX Foci Increases in Ex Vivo Biopsies Relative to In Vivo Tumors. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2616.	1.8	5
95	Cancer Core Europe: A European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century. <i>European Journal of Cancer</i> , 2018, 103, 155-159.	1.3	15
96	“Radiobiology of Proton Therapy” Results of an international expert workshop. <i>Radiotherapy and Oncology</i> , 2018, 128, 56-67.	0.3	85
97	Optimizing clinical research and generating prospective high-quality data in particle therapy in Europe: Introducing the European Particle Therapy Network (EPTN). <i>Radiotherapy and Oncology</i> , 2018, 128, 1-3.	0.3	19
98	Union of light ion therapy centers in Europe (ULICE EC FP7) “ Objectives and achievements of joint research activities. <i>Radiotherapy and Oncology</i> , 2018, 128, 83-100.	0.3	6
99	Subjugation of TGF β 2 Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End Joining. <i>Clinical Cancer Research</i> , 2018, 24, 6001-6014.	3.2	71
100	In vivo imaging in the oral cavity by endoscopic optical coherence tomography. <i>Journal of Biomedical Optics</i> , 2018, 23, 1.	1.4	20
101	Stem cells in radiotherapy. , 2018, , 171-181.		2
102	Research Facility for Radiobiological Studies at the University Proton Therapy Dresden. <i>International Journal of Particle Therapy</i> , 2018, 5, 172-182.	0.9	26
103	Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 63-73.	6.6	247
104	Farewell to Prof. Jens Overgaard. <i>Radiotherapy and Oncology</i> , 2017, 122, 1.	0.3	0
105	FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2017, 122, 437-444.	0.3	10
106	Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. <i>Cancer Research</i> , 2017, 77, 2018-2028.	0.4	80
107	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2017, 141, 594-603.	2.3	91
108	Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model. <i>Oncotimmunology</i> , 2017, 6, e1342909.	2.1	22

#	ARTICLE	IF	CITATIONS
109	Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1813-1822.	3.3	12
110	The clinical target volume in lung, head-and-neck, and esophageal cancer: Lessons from pathological measurement and recurrence analysis. <i>Clinical and Translational Radiation Oncology</i> , 2017, 3, 1-8.	0.9	12
111	Clinical Implementation of Dual-energy CT for Proton Treatment Planning on Pseudo-monoenergetic CT scans. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 427-434.	0.4	98
112	A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. <i>Scientific Reports</i> , 2017, 7, 13206.	1.6	163
113	Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging. <i>Radiotherapy and Oncology</i> , 2017, 124, 533-540.	0.3	123
114	Proton radiography for inline treatment planning and positioning verification of small animals. <i>Acta Oncologica</i> , 2017, 56, 1399-1405.	0.8	11
115	Ex vivo $\hat{H}2AX$ radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity. <i>Radiotherapy and Oncology</i> , 2017, 124, 386-394.	0.3	18
116	Modeling <i>in vivo</i> relative biological effectiveness in particle therapy for clinically relevant endpoints. <i>Acta Oncologica</i> , 2017, 56, 1392-1398.	0.8	18
117	Tumor heterogeneity determined with a $\hat{H}2AX$ foci assay: A study in human head and neck squamous cell carcinoma (hHNSCC) models. <i>Radiotherapy and Oncology</i> , 2017, 124, 379-385.	0.3	11
118	SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2017, 5, 28-36.	0.9	16
119	EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models. <i>Radiotherapy and Oncology</i> , 2017, 124, 496-503.	0.3	21
120	Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 36-42.	0.9	9
121	Modeling tumor control probability for spatially inhomogeneous risk of failure based on clinical outcome data. <i>Zeitschrift Fur Medizinische Physik</i> , 2017, 27, 285-299.	0.6	5
122	Session 39: Modelling and simulation III. <i>Biomedizinische Technik</i> , 2017, 62, .	0.9	0
123	Impact of robust treatment planning on single- and multi-field optimized plans for proton beam therapy of unilateral head and neck target volumes. <i>Radiation Oncology</i> , 2017, 12, 190.	1.2	25
124	Bildung und Steuerung des Universitäts KrebsCentrum Dresden. , 2017, , 639-649.		2
125	Precise image-guided irradiation of small animals: a flexible non-profit platform. <i>Physics in Medicine and Biology</i> , 2016, 61, 3084-3108.	1.6	39
126	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2016, 121, 364-373.	0.3	130

#	ARTICLE	IF	CITATIONS
127	Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2016, 1, 19-26.	0.9	22
128	Impact of pre- and early per-treatment FDG-PET based dose-escalation on local tumour control in fractionated irradiated FaDu xenograft tumours. <i>Radiotherapy and Oncology</i> , 2016, 121, 447-452.	0.3	8
129	Vertebral fractures – An underestimated side-effect in patients treated with radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 421-423.	0.3	8
130	Electronic real-time assessment of patient-reported outcomes in routine care – first findings and experiences from the implementation in a comprehensive cancer center. <i>Supportive Care in Cancer</i> , 2016, 24, 3047-56.	1.0	38
131	Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials. <i>Clinical Cancer Research</i> , 2016, 22, 3138-3147.	3.2	68
132	Fractionation Concepts. <i>Medical Radiology</i> , 2016, , 17-34.	0.0	1
133	A Questionnaire Study to Assess the Value of the Vulnerable Elders Survey, G8, and Predictors of Toxicity as Screening Tools for Frailty and Toxicity in Geriatric Cancer Patients. <i>Oncology Research and Treatment</i> , 2016, 39, 210-216.	0.8	19
134	The Role of Cancer Stem Cells in Tumour Radioresponse. , 2016, , 43-74.		0
135	PRONTOX – proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 543.	0.7	20
136	Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors. <i>Recent Results in Cancer Research</i> , 2016, 198, 107-122.	1.8	12
137	Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 552-560.	1.0	13
138	An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET. <i>EJNMMI Research</i> , 2016, 6, 19.	1.1	46
139	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(+) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DTK-ROG. <i>Clinical Cancer Research</i> , 2016, 22, 2639-2649.	3.2	127
140	First clinical application of a prompt gamma based in vivo proton range verification system. <i>Radiotherapy and Oncology</i> , 2016, 118, 232-237.	0.3	208
141	Toward Distributed Conduction of Large-Scale Studies in Radiation Therapy and Oncology: Open-Source System Integration Approach. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2016, 20, 1397-1403.	3.9	12
142	Radiation oncology in the era of precision medicine. <i>Nature Reviews Cancer</i> , 2016, 16, 234-249.	12.8	636
143	An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells. <i>Cancer Research</i> , 2016, 76, 2637-2651.	0.4	62
144	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). <i>International Journal of Cancer</i> , 2016, 138, 171-181.	2.3	184

#	ARTICLE	IF	CITATIONS
145	Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2016, 118, 350-358.	0.3	62
146	Clinical trials for personalized glioblastoma radiotherapy: Markers for efficacy and late toxicity but often delayed treatment – Does that matter?. <i>Radiotherapy and Oncology</i> , 2016, 118, 211-213.	0.3	3
147	Bridging the valley of death: The new <i>Radiotherapy & Oncology</i> section – “First in man” Translational innovations in radiation oncology. <i>Radiotherapy and Oncology</i> , 2016, 118, 217-219.	0.3	4
148	Cancer: Education and Primary Prevention Starts in Childhood and Adolescence. <i>Journal of Cancer Therapy</i> , 2016, 07, 851-856.	0.1	0
149	Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme. <i>Radiation Oncology</i> , 2015, 10, 172.	1.2	36
150	Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy. <i>Frontiers in Oncology</i> , 2015, 5, 256.	1.3	18
151	Identification of Patient Benefit From Proton Therapy for Advanced Head and Neck Cancer Patients Based on Individual and Subgroup Normal Tissue Complication Probability Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1165-1174.	0.4	89
152	SABR in NSCLC – The beginning of the end or the end of the beginning?. <i>Radiotherapy and Oncology</i> , 2015, 114, 135-137.	0.3	22
153	Aldehyde Dehydrogenase Is Regulated by β -Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. <i>Cancer Research</i> , 2015, 75, 1482-1494.	0.4	195
154	Comparison study of in vivo dose response to laser-driven versus conventional electron beam. <i>Radiation and Environmental Biophysics</i> , 2015, 54, 155-166.	0.6	27
155	Hyperfractionated Accelerated Radiation Therapy (HART) of 70.6 Gy With Concurrent 5-FU/Mitomycin C Is Superior to HART of 77.6 Gy Alone in Locally Advanced Head and Neck Cancer: Long-term Results of the ARO 95-06 Randomized Phase III Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 916-924.	0.4	37
156	Corrigendum to – “HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)” [Radiother. Oncol. 113 (2014) 317–323]. <i>Radiotherapy and Oncology</i> , 2015, 114, 419.	0.3	0
157	Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest. <i>Radiotherapy and Oncology</i> , 2015, 115, 120-127.	0.3	47
158	γ H2AX assay in ex vivo irradiated tumour specimens: A novel method to determine tumour radiation sensitivity in patient-derived material. <i>Radiotherapy and Oncology</i> , 2015, 116, 473-479.	0.3	38
159	Increased evidence for the prognostic value of primary tumor asphericity in pretherapeutic FDG PET for risk stratification in patients with head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 429-437.	3.3	42
160	Implementation of a software for REmote COMparison of PARTicle and photon treatment plans: ReCompare. <i>Zeitschrift Fur Medizinische Physik</i> , 2015, 25, 287-294.	0.6	9
161	Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure. <i>Acta Oncologica</i> , 2015, 54, 1355-1363.	0.8	57
162	Global Task Force on Radiotherapy for Cancer Control. <i>Lancet Oncology</i> , The, 2015, 16, 1144-1146.	5.1	36

#	ARTICLE	IF	CITATIONS
163	Expanding global access to radiotherapy. <i>Lancet Oncology</i> , The, 2015, 16, 1153-1186.	5.1	709
164	Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1150-1156.	2.8	59
165	NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy. <i>Acta Oncologica</i> , 2015, 54, 1658-1664.	0.8	36
166	Residual γ H2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness. <i>Radiotherapy and Oncology</i> , 2015, 116, 480-485.	0.3	37
167	Radiation-induced lung damage – Clinical risk profiles and predictive imaging on their way to risk-adapted individualized treatment planning?. <i>Radiotherapy and Oncology</i> , 2015, 117, 1-3.	0.3	21
168	Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2015, 6, 34494-34509.	0.8	88
169	HPV and beyond-looking out for biomarkers for distinguishing the good prognosis from the bad prognosis group in locally advanced and clinically high risk HNSCC. <i>Annals of Translational Medicine</i> , 2015, 3, 255.	0.7	2
170	Creating a data exchange strategy for radiotherapy research: Towards federated databases and anonymised public datasets. <i>Radiotherapy and Oncology</i> , 2014, 113, 303-309.	0.3	79
171	Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro. <i>International Journal of Radiation Biology</i> , 2014, 90, 678-686.	1.0	8
172	EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation. <i>Cancer Research</i> , 2014, 74, 2825-2834.	0.4	61
173	Guidelines for equipment and staffing of radiotherapy facilities in the European countries: Final results of the ESTRO-HERO survey. <i>Radiotherapy and Oncology</i> , 2014, 112, 165-177.	0.3	61
174	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2014, 113, 317-323.	0.3	141
175	Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy. <i>Pharmaceuticals</i> , 2014, 7, 311-338.	1.7	62
176	BAY 872243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts. <i>Radiation Oncology</i> , 2014, 9, 207.	1.2	50
177	Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts. <i>Radiation Oncology</i> , 2014, 9, 261.	1.2	9
178	What next?. <i>Radiotherapy and Oncology</i> , 2014, 110, 1-2.	0.3	12
179	Concept for individualized patient allocation: ReCompare – remote comparison of particle and photon treatment plans. <i>Radiation Oncology</i> , 2014, 9, 59.	1.2	16
180	Application of organ tolerance dose-constraints in clinical studies in radiation oncology. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 621-627.	1.0	10

#	ARTICLE	IF	CITATIONS
181	Radiogenomics: Radiobiology Enters the Era of Big Data and Team Science. International Journal of Radiation Oncology Biology Physics, 2014, 89, 709-713.	0.4	99
182	Be smart against cancer! A school-based program covering cancer-related risk behavior. BMC Public Health, 2014, 14, 392.	1.2	17
183	Establishment of a small animal tumour model for in vivo studies with low energy laser accelerated particles. Radiation Oncology, 2014, 9, 57.	1.2	18
184	Effect of [18F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice. Radiotherapy and Oncology, 2014, 111, 81-87.	0.3	34
185	Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential. Radiotherapy and Oncology, 2014, 110, 362-369.	0.3	49
186	Hypoxia-Inducible Factor Pathway Inhibition Resolves Tumor Hypoxia and Improves Local Tumor Control After Single-Dose Irradiation. International Journal of Radiation Oncology Biology Physics, 2014, 88, 159-166.	0.4	29
187	Sun Protection Training Based on a Theater Play for Preschoolers: an Effective Method for Imparting Knowledge on Sun Protection?. Journal of Cancer Education, 2013, 28, 435-438.	0.6	9
188	Discovery of the cancer stem cell related determinants of radioresistance. Radiotherapy and Oncology, 2013, 108, 378-387.	0.3	159
189	Reproducibility of target coverage in stereotactic spot scanning proton lung irradiation under high frequency jet ventilation. Radiotherapy and Oncology, 2013, 109, 45-50.	0.3	14
190	GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: Subgroup analysis of the prospective randomized CHARTWEL trial. Radiotherapy and Oncology, 2013, 106, 299-304.	0.3	49
191	Place of Proton Radiotherapy in Future Radiotherapy Practice. Seminars in Radiation Oncology, 2013, 23, 149-153.	1.0	11
192	Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma. Radiotherapy and Oncology, 2013, 106, 147-154.	0.3	66
193	Clinical perspectives of cancer stem cell research in radiation oncology. Radiotherapy and Oncology, 2013, 108, 388-396.	0.3	93
194	Time in radiation oncology – Keep it short!. Radiotherapy and Oncology, 2013, 106, 271-275.	0.3	34
195	Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation. Radiotherapy and Oncology, 2013, 108, 422-428.	0.3	14
196	Molecular radiation biology/oncology at its best: Cutting edge research presented at the 13th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology. Radiotherapy and Oncology, 2013, 108, 357-361.	0.3	5
197	Residual γ H2AX foci predict local tumour control after radiotherapy. Radiotherapy and Oncology, 2013, 108, 434-439.	0.3	37
198	Towards clinical evidence in particle therapy: ENLIGHT, PARTNER, ULICE and beyond. Journal of Radiation Research, 2013, 54, i6-i12.	0.8	10

#	ARTICLE	IF	CITATIONS
199	Inactivation of HNSCC Cells by 90Y-Labeled Cetuximab Strictly Depends on the Number of Induced DNA Double-Strand Breaks. <i>Journal of Nuclear Medicine</i> , 2013, 54, 416-423.	2.8	14
200	Monitoring PAI-1 and VEGF Levels in 6 Human Squamous Cell Carcinoma Xenografts During Fractionated Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e409-e417.	0.4	5
201	Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. <i>Radiotherapy and Oncology</i> , 2012, 102, 444-449.	0.3	26
202	Radiotherapy in small cell lung cancer: Limited volumes in limited disease and adding thoracic radiotherapy in extended disease?. <i>Radiotherapy and Oncology</i> , 2012, 102, 165-167.	0.3	3
203	Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. <i>Radiotherapy and Oncology</i> , 2012, 105, 21-28.	0.3	262
204	Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 2788-2797.	0.8	227
205	The Impact of Cell-Cell Contact, E-Cadherin and EGF Receptor on the Cellular Radiosensitivity of A431 Cancer Cells. <i>Radiation Research</i> , 2012, 178, 224-233.	0.7	8
206	Quantitative modifications of TNM staging, clinical staging and therapeutic intent by FDG-PET/CT in patients with non small cell lung cancer scheduled for radiotherapy – A retrospective study. <i>Lung Cancer</i> , 2012, 78, 148-152.	0.9	24
207	Individualization of cancer treatment from radiotherapy perspective. <i>Molecular Oncology</i> , 2012, 6, 211-221.	2.1	68
208	Rapid re-expression of CD133 protein in colorectal cancer cell lines in vitro and in vivo. <i>Laboratory Investigation</i> , 2012, 92, 1607-1622.	1.7	15
209	Radiobiological Effectiveness of Laser Accelerated Electrons in Comparison to Electron Beams from a Conventional Linear Accelerator. <i>Journal of Radiation Research</i> , 2012, 53, 395-403.	0.8	50
210	Cancer Stem Cells as a Predictive Factor in Radiotherapy. <i>Seminars in Radiation Oncology</i> , 2012, 22, 151-174.	1.0	83
211	β 1 Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. <i>Journal of Clinical Investigation</i> , 2012, 122, 1529-1540.	3.9	194
212	3D Semi-quantification of Nanoparticle Content in Tissue on Experimental and Commercial β 4CT-Scanner. <i>Springer Proceedings in Physics</i> , 2012, , 111-115.	0.1	0
213	Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. <i>Radiotherapy and Oncology</i> , 2011, 99, 323-330.	0.3	78
214	Tumour-infiltrating CD11b+ myelomonocytes and response to fractionated irradiation of human squamous cell carcinoma (hSCC) xenografts. <i>Radiotherapy and Oncology</i> , 2011, 101, 80-85.	0.3	11
215	Residual DNA double strand breaks in perfused but not in unperfused areas determine different radiosensitivity of tumours. <i>Radiotherapy and Oncology</i> , 2011, 100, 137-144.	0.3	40
216	Prognostic Value of Radiobiological Hypoxia during Fractionated Irradiation for Local Tumor Control. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 306-310.	1.0	36

#	ARTICLE	IF	CITATIONS
217	Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1203-1211.	3.3	108
218	Exploratory Study of the Prognostic Value of Microenvironmental Parameters During Fractionated Irradiation in Human Squamous Cell Carcinoma Xenografts. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1205-1213.	0.4	61
219	Cellular and Tumor Radiosensitivity is Correlated to Epidermal Growth Factor Receptor Protein Expression Level in Tumors Without EGFR Amplification. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1181-1188.	0.4	38
220	EGF Receptor Inhibition Radiosensitizes NSCLC Cells by Inducing Senescence in Cells Sustaining DNA Double-Strand Breaks. <i>Cancer Research</i> , 2011, 71, 6261-6269.	0.4	105
221	Cancer Stem Cells: Targets and Potential Biomarkers for Radiotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 7224-7229.	3.2	106
222	Transferring university knowledge to develop new technologies: the model of the "OncoRay – Joint Center for Radiation Research in Oncology". <i>International Journal of Healthcare Technology and Management</i> , 2010, 11, 328.	0.1	0
223	Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 1019-1028.	1.2	26
224	Fractionation Concepts. <i>Medical Radiology</i> , 2010, , 13-26.	0.0	0
225	Cancer stem cells at the crossroads of current cancer therapy failures” Radiation oncology perspective. <i>Seminars in Cancer Biology</i> , 2010, 20, 116-124.	4.3	97
226	CD44: A Cancer Stem Cell”Related Biomarker with Predictive Potential for Radiotherapy. <i>Clinical Cancer Research</i> , 2010, 16, 5091-5093.	3.2	93
227	Usefulness of dynamic contrast enhanced computed tomography in patients with non-small-cell lung cancer scheduled for radiation therapy. <i>Lung Cancer</i> , 2010, 70, 280-285.	0.9	17
228	CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell line HCT-116. <i>Radiotherapy and Oncology</i> , 2010, 94, 375-383.	0.3	32
229	Glycolytic metabolism and tumour response to fractionated irradiation. <i>Radiotherapy and Oncology</i> , 2010, 94, 102-109.	0.3	181
230	ErbB2 expression through heterodimerization with erbB1 is necessary for ionizing radiation- but not EGF-induced activation of Akt survival pathway. <i>Radiotherapy and Oncology</i> , 2010, 97, 338-345.	0.3	49
231	First report on the patient database for the identification of the genetic pathways involved in patients over-reacting to radiotherapy: GENEPII. <i>Radiotherapy and Oncology</i> , 2010, 97, 36-39.	0.3	23
232	Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. <i>Radiotherapy and Oncology</i> , 2010, 96, 116-122.	0.3	80
233	Correlating quantitative MR measurements of standardized tumor lines with histological parameters and tumor control dose. <i>Radiotherapy and Oncology</i> , 2010, 96, 123-130.	0.3	12
234	Fractionation in prostate cancer ” Is it time after all?. <i>Radiotherapy and Oncology</i> , 2010, 96, 1-5.	0.3	24

#	ARTICLE	IF	CITATIONS
235	Effect of cetuximab and fractionated irradiation on tumour micro-environment. <i>Radiotherapy and Oncology</i> , 2010, 97, 322-329.	0.3	28
236	PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1. <i>Journal of Clinical Investigation</i> , 2010, 120, 2516-2527.	3.9	89
237	Co-localisation of hypoxia and perfusion markers with parameters of glucose metabolism in human squamous cell carcinoma (hSCC) xenografts. <i>International Journal of Radiation Biology</i> , 2009, 85, 972-980.	1.0	43
238	Serial FDG-PET on patients with head and neck cancer: Implications for radiation therapy. <i>International Journal of Radiation Biology</i> , 2009, 85, 796-804.	1.0	40
239	Imaging radiation biology for optimised radiation therapy. <i>International Journal of Radiation Biology</i> , 2009, 85, 729-731.	1.0	1
240	Comparison of [¹⁸ F]FDG uptake and distribution with hypoxia and proliferation in FaDu human squamous cell carcinoma (hSCC) xenografts after single dose irradiation. <i>International Journal of Radiation Biology</i> , 2009, 85, 772-780.	1.0	17
241	Cancer stem cells and radiotherapy. <i>International Journal of Radiation Biology</i> , 2009, 85, 391-402.	1.0	75
242	Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by γ -H2AX staining. <i>International Journal of Radiation Biology</i> , 2009, 85, 1032-1041.	1.0	70
243	Impact of exogenous lactate on survival and radioresponse of carcinoma cells in vitro. <i>International Journal of Radiation Biology</i> , 2009, 85, 989-1001.	1.0	14
244	Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors. <i>International Journal of Radiation Biology</i> , 2009, 85, 943-954.	1.0	38
245	The extreme radiosensitivity of the squamous cell carcinoma SKX is due to a defect in double-strand break repair. <i>Radiotherapy and Oncology</i> , 2009, 90, 257-264.	0.3	48
246	Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas. <i>Radiotherapy and Oncology</i> , 2009, 92, 405-410.	0.3	22
247	Radiotherapy of lung cancer: Technology meets biology meets multidisciplinary. <i>Radiotherapy and Oncology</i> , 2009, 91, 279-281.	0.3	24
248	The use of a comprehensive tumour xenograft dataset to validate gene signatures relevant for radiation response. <i>Radiotherapy and Oncology</i> , 2009, 92, 417-422.	0.3	18
249	CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116. <i>Radiotherapy and Oncology</i> , 2009, 92, 353-361.	0.3	49
250	Core needle biopsies for determination of the microenvironment in individual tumours for longitudinal radiobiological studies. <i>Radiotherapy and Oncology</i> , 2009, 92, 460-465.	0.3	13
251	Tumor Biology's Impact on Clinical Cure Rates. <i>Medical Radiology</i> , 2009, , 323-334.	0.0	6
252	Modified fractionation. , 2009, , 135-148.		7

#	ARTICLE	IF	CITATIONS
253	Combined radiotherapy and chemotherapy. , 2009, , 246-258.		5
254	Molecular-targeted agents for enhancing tumour response. , 2009, , 287-300.		3
255	Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 387-402.	2.7	26
256	Effects of Lovastatin Alone or Combined with Irradiation on Tumor Cells in Vitro and in Vivo. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 48-53.	1.0	27
257	Clonogens and cancer stem cells. <i>Nature Reviews Cancer</i> , 2008, 8, 990-990.	12.8	9
258	Exploring the role of cancer stem cells in radioresistance. <i>Nature Reviews Cancer</i> , 2008, 8, 545-554.	12.8	766
259	PI3K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cells in vitro. <i>DNA Repair</i> , 2008, 7, 1746-1756.	1.3	54
260	PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck. <i>Radiotherapy and Oncology</i> , 2008, 86, 361-368.	0.3	20
261	Additional PET/CT in week 5â€“6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?. <i>Radiotherapy and Oncology</i> , 2008, 88, 335-341.	0.3	74
262	The future of IGRT â€“ Cost Benefit Analysis. <i>Acta OncolÃ³gica</i> , 2008, 47, 1188-1192.	0.8	17
263	Inactivation of AP1 Proteins by a Nuclear Serine Protease Precedes the Onset of Radiation-Induced Fibrosing Alveolitis1. <i>Radiation Research</i> , 2008, 169, 531-542.	0.7	7
264	Regionales Brustzentrum am Universit¨s-KrebsCentrum Dresden. <i>Breast Care</i> , 2008, 3, 11-11.	0.8	10
265	Pharmacological inhibition of EGFR tyrosine kinase affects ILK-mediated cellular radiosensitization in vitro. <i>International Journal of Radiation Biology</i> , 2007, 83, 793-802.	1.0	29
266	Adoptive transfer of cytotoxic T-cells for treatment of residual disease after irradiation. <i>International Journal of Radiation Biology</i> , 2007, 83, 827-836.	1.0	7
267	Stimulated PI3K-AKT Signaling Mediated through Ligand or Radiation-Induced EGFR Depends Indirectly, but not Directly, on Constitutive K-Ras Activity. <i>Molecular Cancer Research</i> , 2007, 5, 863-872.	1.5	90
268	Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: Possible role for thrombosis. <i>Radiotherapy and Oncology</i> , 2007, 82, 96-104.	0.3	43
269	EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms. <i>Radiotherapy and Oncology</i> , 2007, 83, 238-248.	0.3	170
270	EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: Differential response of cancer stem cells and nontumourigenic cells?. <i>Radiotherapy and Oncology</i> , 2007, 83, 316-325.	0.3	51

#	ARTICLE	IF	CITATIONS
271	Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. <i>Radiotherapy and Oncology</i> , 2007, 83, 304-310.	0.3	144
272	Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. <i>Radiotherapy and Oncology</i> , 2007, 83, 311-315.	0.3	59
273	Translational research in radiotherapy – Getting closer to the bedside. <i>Radiotherapy and Oncology</i> , 2007, 83, 217-219.	0.3	6
274	Age-Related Changes in the Frequency of Mesenchymal Stem Cells in the Bone Marrow of Rats. <i>Stem Cells and Development</i> , 2007, 16, 439-446.	1.1	76
275	Combination of EGFR/HER2 Tyrosine Kinase Inhibition by BIBW 2992 and BIBW 2669 with Irradiation in FaDu Human Squamous Cell Carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 256-264.	1.0	64
276	Experimental Evaluation of Functional Imaging for Radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 41-42.	1.0	6
277	Keynote comment: Radiotherapy in the age of molecular oncology. <i>Lancet Oncology, The</i> , 2006, 7, 786-787.	5.1	14
278	Influence of connective tissue diseases on the expression of radiation side effects: A systematic review. <i>Radiotherapy and Oncology</i> , 2006, 78, 123-130.	0.3	66
279	Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. <i>Radiotherapy and Oncology</i> , 2006, 80, 112-122.	0.3	78
280	Antiproliferative effects of EGFR tyrosine kinase inhibition and radiation-induced genotoxic injury are attenuated by adhesion to fibronectin. <i>Radiotherapy and Oncology</i> , 2006, 80, 178-184.	0.3	39
281	Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: The need for a multivariate approach in biomarker studies. <i>Radiotherapy and Oncology</i> , 2006, 81, 122-129.	0.3	102
282	Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. <i>Radiotherapy and Oncology</i> , 2006, 81, 130-135.	0.3	158
283	Portal Verification of High-Energy Electron Beams Using their Photon Contamination by Film-Cassette Systems. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 37-44.	1.0	6
284	Blockage of Epidermal Growth Factor Receptor-Phosphatidylinositol 3-Kinase-AKT Signaling Increases Radiosensitivity of K-RAS Mutated Human Tumor Cells In vitro by Affecting DNA Repair. <i>Clinical Cancer Research</i> , 2006, 12, 4119-4126.	3.2	196
285	Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 908-914.	0.4	46
286	Ultrafractionation does not Improve the Results of Radiotherapy in Radioresistant Murine DDL1 Lymphoma. <i>Strahlentherapie Und Onkologie</i> , 2005, 181, 540-544.	1.0	17
287	Hyperfractionated Accelerated Chemoradiation With Concurrent Fluorouracil-Mitomycin Is More Effective Than Dose-Escalated Hyperfractionated Accelerated Radiation Therapy Alone in Locally Advanced Head and Neck Cancer: Final Results of the Radiotherapy Cooperative Clinical Trials Group of the German Cancer Society 95-06 Prospective Randomized Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 1125-1135.	0.8	269
288	Enhanced Susceptibility of Irradiated Tumor Vessels to Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibition. <i>Cancer Research</i> , 2005, 65, 5374-5379.	0.4	54

#	ARTICLE	IF	CITATIONS
289	Recovery from sublethal damage during fractionated irradiation of human FaDu SCC. <i>Radiotherapy and Oncology</i> , 2005, 74, 331-336.	0.3	20
290	Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. <i>Radiotherapy and Oncology</i> , 2005, 74, 117-129.	0.3	84
291	Towards equity in turbulent Europe. <i>Radiotherapy and Oncology</i> , 2005, 75, 251-252.	0.3	9
292	Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?. <i>Radiotherapy and Oncology</i> , 2005, 76, 206-212.	0.3	40
293	Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. <i>Radiotherapy and Oncology</i> , 2005, 76, 143-150.	0.3	133
294	Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. <i>Radiotherapy and Oncology</i> , 2005, 76, 162-167.	0.3	85
295	Kinetics of EGFR expression during fractionated irradiation varies between different human squamous cell carcinoma lines in nude mice. <i>Radiotherapy and Oncology</i> , 2005, 76, 151-156.	0.3	27
296	Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo. <i>International Journal of Radiation Biology</i> , 2005, 81, 751-758.	1.0	35
297	New anticancer agents: in vitro and in vivo evaluation. <i>In Vivo</i> , 2005, 19, 1-7.	0.6	67
298	TCP and NTCP: a basic introduction. <i>Rays</i> , 2005, 30, 99-104.	0.2	25
299	TCP and NTCP in preclinical and clinical research in Europe. <i>Rays</i> , 2005, 30, 121-6.	0.2	7
300	In Vivo Verification of Electron Beam Energy by Patient Exit Dose and Optical Density of Portal Films. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 62-65.	1.0	4
301	Effect of the Hypoxic Cell Sensitizer Isometronidazole on Local Control of Two Human Squamous Cell Carcinomas after Fractionated Irradiation. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 375-382.	1.0	17
302	Impact of Hypoxia and the Metabolic Microenvironment on Radiotherapy of Solid Tumors. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 609-615.	1.0	21
303	Molecular targeting in radiotherapy of lung cancer. <i>Lung Cancer</i> , 2004, 45, S187-S197.	0.9	23
304	Shaping the future: training of professionals for radiotherapy in Europe. <i>Radiotherapy and Oncology</i> , 2004, 70, 103-105.	0.3	7
305	Hyperbaric oxygen therapy in the treatment of radio-induced lesions in normal tissues: a literature review. <i>Radiotherapy and Oncology</i> , 2004, 72, 1-13.	0.3	116
306	Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. <i>Radiotherapy and Oncology</i> , 2004, 72, 257-266.	0.3	161

#	ARTICLE	IF	CITATIONS
307	Physical and Technical Quality Assurance in the CHARTWEL-Bronchus Trial. <i>Strahlentherapie Und Onkologie</i> , 2003, 179, 152-157.	1.0	5
308	Ultrafractionation in human malignant glioma xenografts. <i>International Journal of Cancer</i> , 2003, 107, 333-333.	2.3	11
309	In regard to Solomon et al.: EGFR blockade with ZD1839 (â€œressaâ€) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. <i>IJROBP</i> 2003;55:713â€“723. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 300-301.	0.4	5
310	Towards genetic prediction of radiation responses: ESTRO's GENEPI project. <i>Radiotherapy and Oncology</i> , 2003, 69, 121-125.	0.3	89
311	Selection of Genetically Distinct, Rapidly Proliferating Clones does not Contribute to Repopulation during Fractionated Irradiation in FaDu Squamous Cell Carcinoma. <i>Radiation Research</i> , 2003, 160, 257-262.	0.7	1
312	New Targets for the Modulation of Radiation Response - Selective Inhibition of the Enzyme Cyclooxygenase 2. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2003, 3, 354-359.	7.0	11
313	Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. <i>Anticancer Research</i> , 2003, 23, 3869-76.	0.5	43
314	Splicing Mutations in TP53 in Human Squamous Cell Carcinoma Lines Influence Immunohistochemical Detection. <i>Journal of Histochemistry and Cytochemistry</i> , 2002, 50, 197-204.	1.3	64
315	2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography in Target Volume Definition for Radiotherapy of Patients with Non-Small-Cell Lung Cancer. <i>Molecular Imaging and Biology</i> , 2002, 4, 257-263.	1.3	37
316	Immunohistochemically Detected p53 Mutations in Epithelial Tumors and Results of Treatment with Chemotherapy and Radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2002, 178, 411-421.	1.0	24
317	No evidence for a different magnitude of the time factor for continuously fractionated irradiation and protocols including gaps in two human squamous cell carcinoma in nude mice. <i>Radiotherapy and Oncology</i> , 2001, 59, 187-194.	0.3	13
318	Predictive factors in radiotherapy for non-small cell lung cancer: present status. <i>Lung Cancer</i> , 2001, 31, 43-56.	0.9	91
319	Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer. <i>Lung Cancer</i> , 2001, 33, S35-S45.	0.9	27
320	Therapy of localized non-small cell lung cancer (take home messages). <i>Lung Cancer</i> , 2001, 33, S47-S49.	0.9	9
321	The results of colorectal cancer treatment by p53 status. <i>Diseases of the Colon and Rectum</i> , 2001, 44, 322-333.	0.7	52
322	The translational research chain: is it delivering the goods?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 345-351.	0.4	33
323	Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 483-493.	0.4	101
324	Rat model of lung fibrosis: comparison of functional, biochemical, and histopathological changes 4 months after single irradiation of the right hemithorax. <i>Toxicology</i> , 2001, 161, 153-163.	2.0	25

#	ARTICLE	IF	CITATIONS
325	Wild-Type Sequence ofTP53, Intron 7. Radiation Research, 2001, 155, 641-641.	0.7	1
326	Radiobiological Hypoxia, Oxygen Tension, Interstitial Fluid Pressure and Relative Viable Tumour Area in Two Human Squamous Cell Carcinomas in Nude Mice During Fractionated Radiotherapy. Acta Oncologica, 2001, 40, 519-528.	0.8	25
327	Hyperfractionated radiotherapy: Tops or flops?. , 1999, 33, 399-402.		6
328	Impact of overall treatment time on local control of slow growing human GL squamous cell carcinoma in nude mice treated by fractionated irradiation. Radiotherapy and Oncology, 1999, 50, 107-111.	0.3	24
329	Comparison of the Response of human FaDu squamous cell carcinoma in nude mice after hypofractionated-accelerated regimens and "curative" fractionation schedules. Strahlentherapie Und Onkologie, 1998, 174, 315-319.	1.0	12
330	Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data. Radiotherapy and Oncology, 1998, 46, 127-130.	0.3	45
331	Fractionation Effect on Radiation-Induced Growth Retardation of Tibia in Rabbits and Rats. Acta Oncologica, 1998, 37, 151-158.	0.8	6
332	Effect of irradiated volume on lung damage in pigs. Radiotherapy and Oncology, 1997, 44, 35-40.	0.3	39
333	Local Control as an End Point in Experimental Radiation Therapy of Human Tumor Xenografts. Contributions To Oncology / Beitrage Zur Onkologie, 1996, , 154-160.	0.1	5
334	In vivo radiation sensitivity of glioblastoma multiforme. International Journal of Radiation Oncology Biology Physics, 1995, 32, 99-104.	0.4	70
335	Impact of overall treatment time of fractionated irradiation on local control of human FaDu squamous cell carcinoma in nude mice. Radiotherapy and Oncology, 1994, 32, 137-143.	0.3	67
336	Present Results of Neutron Therapy: The German experience. Acta Oncologica, 1994, 33, 281-287.	0.8	10
337	Impact of Tumor Stroma on Expression of the Tumor Bed Effect in R1H Rat Rhabdomyosarcoma. Radiation Research, 1994, 140, 432.	0.7	7
338	Response to Lindstrom and Fowler's "the influence of dose and time on local control of carcinoma of the larynx by radiation therapy". International Journal of Radiation Oncology Biology Physics, 1992, 22, 1163.	0.4	0
339	Response of xenografts of human malignant gliomas and squamous cell carcinomas to fractionated irradiation. International Journal of Radiation Oncology Biology Physics, 1992, 23, 803-809.	0.4	53
340	Metastases after fractionated radiation therapy of three murine tumor models. International Journal of Radiation Oncology Biology Physics, 1990, 19, 367-370.	0.4	13
341	Response of Human Squamous Cell Carcinoma Xenografts of Different Sizes to Irradiation: Relationship of Clonogenic Cells, Cellular Radiation Sensitivity in Vivo, and Tumor Rescuing Units. Radiation Research, 1990, 123, 325.	0.7	95
342	18F-Fluorodeoxyglucose Positron Emission Tomography of Head and Neck Cancer: Location and HPV Specific Parameters for Potential Treatment Individualization. Frontiers in Oncology, 0, 12, .	1.3	3